When it comes to appendix cancer and related conditions, some cases are so rare that doctors must design a completely customized treatment plan. This case study tells the story of a 44-year-old woman who faced three unusual diagnoses at the same time:
- Low-grade appendiceal mucinous neoplasm (LAMN) – a tumor that produces mucus inside the appendix
- Pseudomyxoma peritonei (PMP) – a condition where that mucus spreads throughout the abdomen
- A mucinous borderline ovarian tumor (MBOT) – an abnormal but not fully cancerous ovarian growth
This combination is extremely uncommon, which meant there were no standard treatment guidelines to follow.
How Doctors Approached the Case
After the patient arrived with abdominal swelling, imaging and tests showed mucus deposits throughout the abdomen, an abnormal appendix, and a large ovarian cyst. Her tumor markers were also elevated.
The medical team decided on a multimodal approach, meaning several different treatments used together:
1. Major Cytoreductive Surgery (CRS)
Surgeons removed as much visible disease as possible—including the appendix, parts of the colon, ovaries, uterus, and omentum. This “debulking” helps reduce tumor load and prepares the body for next treatments.
2. Systemic Chemotherapy With Modified FOLFIRINOX
Because the tumor burden was significant, the team added a chemotherapy plan that included irinotecan, a drug not traditionally used for low-grade mucinous cancers.
The patient tolerated treatment well, and her tumor markers returned to normal after three cycles.
3. Planned Second-Look Surgery + HIPEC
After chemo and healing time, she returned for a second surgery to remove remaining disease and receive HIPEC, a heated chemotherapy wash placed directly inside the abdomen. This treatment helps destroy microscopic cancer cells that can cause future recurrence.
The Outcome
One year after her initial surgery, the patient was disease-free, with normal tumor markers and no symptoms. Her success highlights how flexible, creative treatment planning—supported by a multidisciplinary team—can save lives, especially when dealing with rare cancers in resource-limited environments.
Why This Case Matters
- It shows that irinotecan-based chemotherapy may be useful in select low-grade mucinous cancers.
- It underscores how essential teamwork is when there are no standard protocols.
- It proves that even in low-resource settings, thoughtful planning and staged treatment can lead to excellent results.
This case adds important insight into the treatment of rare appendix-related cancers and encourages future research into better therapies for patients around the world.
Original Case Study: Annals of Medicine and Surgery
Leave a Reply